spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Thalomid 

 HSMN NewsFeed - 18 Sep 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Oct 2017
Lannett And Celgene Enter Into Settlement And License Agreement Related To Thalomid(R)
Biopharmaceuticals Oncology Generics Licensing
 HSMN NewsFeed - 25 Jul 2012
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2010
Ramius and Royalty Pharma Extend Tender Offer Until January 5, 2011 Pursuant to Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Feb 2010
EntreMed Receives Orphan Drug Designation for ENMD-2076 in Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jan 2010
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Nov 2009
NeurogesX Expands Commercial Operations Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Aug 2009
Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 8 Jul 2008
Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2008
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Apr 2008
Thalidomide Pharmion(TM) Granted Full Marketing Authorization for Treatment of Newly Diagnosed Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Apr 2008
Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Mar 2008
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2008
Celgene Completes $2.9 Billion Acquisition of Pharmion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Jan 2008
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Dec 2007
EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2007
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 16 Oct 2007
EntreMed Appoints Senior Vice President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2007
EntreMed Raises $20 Million to Support Clinical Development Program
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Sep 2007
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2007
Nereus Pharmaceuticals Raises $45 Million in Series D-2 Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Jun 2007
Clinical Results From EntreMed's Panzem(R) NCD and Taxol(R) Breast Cancer Study Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion Announces French ATU Granted for Use of Thalidomide for Elderly Patients With Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2007
EntreMed Presents Phase 2 Results for Panzem(R) Capsules in Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2007
EntreMed Commences Phase 2 Clinical Trial Combining Panzem(R) NCD and Temodar(R) in Brain Cancer Patients
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 May 2007
Royalty Pharma Acquires a Portion of New York University's Royalty Interest in Remicade(R) for $650 Million
Biopharmaceuticals
 HSMN NewsFeed - 1 Mar 2007
EMEA Accepts for Review Thalidomide Pharmion(R) Marketing Authorization Application for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jan 2007
Barr Confirms Generic Thalomid(R) Suit Filed
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Jan 2007
Safety Monitoring Board Recommends Continuation of EntreMed's MKC-1 Phase 2 Breast Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jan 2007
Pharmion Submits European Marketing Authorization Application for Thalidomide Pharmion(R) for Untreated Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jan 2007
NCCN Updates Antiemesis Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Dec 2006
Barr Confirms Generic Thalomid(R) Capsule, 50 mg and 100 mg Application
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 26 Dec 2006
Celgene Notified of ANDA Filing for Thalidomide
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 13 Dec 2006
Barr Confirms Generic Thalomid(R) Capsule Application
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 13 Dec 2006
Celgene Notified of ANDA Filing for Thalidomide
Biopharmaceuticals Generics FDA Litigation
 HSMN NewsFeed - 12 Dec 2006
EntreMed Presents Data on the Combination of Panzem(R) and Velcade(R) in Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2006
EntreMed Commences Phase 2 Clinical Trial With Panzem(R) NCD in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2006
Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA(R) From AstraZeneca and CAT
Biopharmaceuticals
 HSMN NewsFeed - 25 Oct 2006
EntreMed Commences Clinical Trial for MKC-1 in Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2006
EntreMed Commences Panzem(R) NCD Phase 2 Study in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2006
The International Myeloma Foundation Says REVLIMID(R) Approval for Multiple Myeloma Can Be Life-Changing for Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2006
THALOMID(R) (Thalidomide) Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2006
Thalidomide Survival Data Evaluated in Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 May 2006
Thalomid(R) sNDA Granted FDA Approval For Treatment of Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jan 2006
Pharmion Provides EU Registration Strategy Update for Thalidomide
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Jan 2006
THALOMID(R) Pivotal Phase III Multiple Myeloma Trial Reaches Pre-Specified Interim Endpoint
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 34

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 34 additional stories matching:
Thalomid
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.